% | $
Quotes you view appear here for quick access.

OncoSec Medical Incorporated Message Board

  • bob_flemings bob_flemings Feb 19, 2014 11:00 AM Flag

    Turning non-responders into responders

    more than 60% of patients don't respond to anti-PD1s. Dr. Pierce thinks OncoSec's OMS could make these patients "responders", as noted in the Wall Street Cheat Sheet article.

    This could be a great discovery, and a reason for why big pharma is chasing electroporation.

    Read the article.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • jim.beemer Feb 19, 2014 11:03 AM Flag

      The partnerships are very interesting, especially with Roche, as it invested a pretty penny in Inovio.

      If Dr. Pierce is right, companies will begin testing these in combination to make anti-PD1s more effective. If ONCS begins a trial to test this theory in 2014, could you imagine just how attractive it becomes?

      I wouldn't be shocked to see Roche announce a trial with electroporation and its anti-PDL1 in 2015, which will be a massive catalyst for ONCS.

      ONCS could soar to $5 if this occurs.

      Sentiment: Strong Buy

1.56+0.08(+5.41%)10:03 AMEST